PBC和PBC-AIH重叠综合征患者外周血树突状细胞及其亚群变化初步研究*

doi:10.3969/j.issn.1672-5069.2025.04.023

Abstract

Abstract: Objective The aim of this study was to investigate the clinical implication of peripheral blood dendritic cells (DC) and their subsets in patients with primary biliary cholangitis (PBC) and PBC-autoimmune hepatitis overlap syndrome (PBC-AIH OS) . Methods 56 patients with PBC and 20 patients with PBC-AIH OS were encountered in Nantong Third People's Hospital between January 2020 and January 2024, receiving ursodeoxycholic acid (UDCA) or UDCA with immunosuppressant combination treatment for 12 months. Percentages of peripheral blood dendritic cell subpopulations, including plasmacytoid dendritic cells (pDC), conventional dendritic cells (cDC), conventional type 1 dendritic cells (cDC1) and conventional type 2 dendritic cells (cDC2) were detected by flow cytometry. Results Serum ALT, AST, bilirubin, albumin, globulin, bile acid, IgG and IgA levels in patients with PBC-AIH OS were significantly higher than those in patients with PBC (P<0.05); percentages of peripheral blood cDC, pdc, cDC1and cDC2 cells in patients with PBC were 1.1 (0.6, 1.9) %, 0.2 (0.1, 0.4) %, 0.004 (0.003, 0.010) % and 0.2 (0.1, 0.4) %, is significantly higher than [0.7 (0.4, 1.0) %, 0.1 (0.1, 0.2) %, 0.004 (0.0004, 0.007) % and 0.2 (0.1, 0.2) %, P< 0.05)] in patients with PBC- AIH OS; by end of 12-month treatment, complete response (CR) by Paris's criteria was found in 12 cases 60.0%)in patients with PBC-AIH OS, and in 47 cases (83.9%) in patients with PBC; percentages of cDC and cDC2 cells in CR patients with PBC were (1.4±1.0)% and 0.3(0.2,0.4)%, both significantly higher than [(0.6±0.4)% and 0.2(0.1,0.2)%, respectively P<0.05] in non-responders; percentages of cDC and cDC1 cells in CR patients with PBC-AIH OS were 0.7(0.5, 1.0)% and (0.01±0.002)%, both much higher than [0.4(0.2, 0.5)% and(0.0003±0.001)%, respectively, P<0.05] in non-responders. Conclusion DCs and their subpopulations change greatly, which might impact response of UDCA and/or immunosuppressant combination treatment, and needs further investigation.

Key words: Primary biliary cholangitis, Primary biliary cholangitis-autoimmune hepatitis overlap syndrome, Ursodeoxycholic acid, Immunosuppressant, Dendritic cells, Response

Wang Yanyan, Zhou Tongtong, Li Na, et al. A preliminary study on changes of peripheral blood dendritic cells and their subsets in patients with PBC and PBC-AIH overlap syndrome[J]. Journal of Practical Hepatology, 2025, 28(4): 569-572.

References

[1] Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol, 2014, 60(1): 210-223.
[2] 王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析. 实用肝脏病杂志, 2024, 27(5): 721-724.
[3] Yan Y L, Xing X, Wang Y, et al. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome.World J Gastroenterol, 2022, 28(18): 2021-2033.
[4] Sucher E,Sucher R, Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res, 2019, 2019:9437043.
[5] Graham R P, Smyrk T C, Zhang L. Evaluation of langerhans cell infiltrate by CD1a immunostain in liver biopsy for the diagnosis of primary biliary cirrhosis. Am J Surg Pathol, 2012, 36(5): 732-736.
[6] Worbs T, Hammerschmidt S I, Forster R. Dendritic cell migration in health and disease. Nat Rev Immunol, 2017, 17(1): 30-48.
[7] Macri C, Pang E S, Patton T, et al. Dendritic cell subsets. Semin Cell Dev Biol, 2018, 84:11-21.
[8] Chen K, Wang J M, Yuan R, et al. Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol, 2016, 34:1-15.
[9] Rontogianni D, Gerber H, Zimmermann A. Primary biliary cirrhosis (PBC): antigen-presenting cells differ in their distribution in early and late stage PBC and involve the ductal, but not the ductular compartment. Histol Histopathol, 1994, 9(2): 211-220.
[10] Patente T A, Pinho M P, Oliveira A A, et al. Human dendritic cells: their heterogeneity and clinical application potential in cancer immunotherapy. Front Immunol, 2018, 9:3176.
[11] 中华医学会肝病学分会、消化病学分会、感染病学分会.胆汁淤积性肝病诊断和治疗共识(2015年).实用肝脏病杂志,2016,19(6):Ⅰ-ⅩⅠ.
[12] 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021). 中华肝脏病杂志,2022,30(3):264-275.
[13] 中华医学会肝病学分会.自身免疫性肝炎诊断和治疗指南(2021).中华肝脏病杂志,2022,30(5):482-492.
[14] European Associationforthe Studyofthe L. Easlclinical practice guidelines: autoimmune hepatitis. J Hepatol, 2015, 63(4): 971-1004.
[15] Kowdley K V, Bowlus C L, Levy C, et al. Application of the latest advances in evidence-based medicine in primary biliary cholangitis. Am J Gastroenterol, 2023, 118(2): 232-242.
[16] Lleo A, Leung P S C, Hirschfield G M, et al. The pathogenesis of primary biliary cholangitis: acomprehensive review. Semin Liver Dis, 2020, 40(1): 34-48.
[17] Tanaka A. Current understanding of primary biliary cholangitis. Clin Mol Hepatol, 2021, 27(1): 1-21.
[18] Tanaka A, Leung P S C, Gershwin M E. The genetics of primary biliary cholangitis. Curr Opin Gastroenterol, 2019, 35(2): 93-98.
[19] Medford A, Childs J, Little A, et al. Emerging therapeutic strategies in the fight against primary biliary cholangitis. J Clin Transl Hepatol, 2023, 11(4): 949-957.
[20] Talwalkar J A, Lindor K D. Primary biliary cirrhosis. Lancet, 2003, 362(9377): 53-61.
[21] Sherlock S. Primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune cholangitis. Clin Liver Dis, 2000, 4(1): 97-113.
[22] Ma W T, Chen D K. Immunological abnormalities in patients with primary biliary cholangitis. Clin Sci (Lond), 2019, 133(6): 741-760.
[23] Reuveni D, Assi S, Gore Y, et al. Conventional type 1 dendritic cells are essential for the development of primary biliary cholangitis. Liver Int, 2024, 44(8): 2063-2074.

A preliminary study on changes of peripheral blood dendritic cells and their subsets in patients with PBC and PBC-AIH overlap syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Li Xiaojing, Huang Li, Mo Bo, et al. Multivariate Logistic regression analysis of factors impacting response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2025, 28(4): 565-568.
[2]	Peng Zhifang, Wu Li, Sheng Xiuhong. Changes of serum MMP-1 and IL-6 levels in patients with primary biliary cholangitis during ursodeoxycholic acid treatment [J]. Journal of Practical Hepatology, 2025, 28(4): 573-576.
[3]	Dai Zixing, Yuan Hui, Chen Qingling, et al. Correlation of serum volatile organic compounds to body inflammatory index in patients with metabolism-related fatty liver disease: an analysis based on 2017-2020 National Health and Nutrition Examination Survey database [J]. Journal of Practical Hepatology, 2025, 28(3): 350-353.
[4]	Ma Dantong, Yang Shuang, Gao Lili, et al. Clinical feature of patients with drug-induced autoimmune-like hepatitis: An analysis of 73 cases [J]. Journal of Practical Hepatology, 2025, 28(3): 390-393.
[5]	Qi Jing, Zhao Xiaoting, Wang Tingting, et al. Serum NoD-like receptor heat protein domain associated protein 3 level changes in patients with chronic hepatitis C undergoing sorphobuvir/dallatavir therapy [J]. Journal of Practical Hepatology, 2025, 28(2): 194-197.
[6]	Yang Shuang, Gao Xuesong, Duan Xuefei. Refractory primary biliary cholangitis:current landscape and perspective [J]. Journal of Practical Hepatology, 2025, 28(1): 156-159.
[7]	Chen Rongrong, Jiang Lili, Cao Lihua. Serum IL-6, IL-8 and IL-10 levels and their impact on response to steroid therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(6): 852-855.
[8]	Chen Datong, Yue Zhanyi, Zhang Xiaopeng. Single nucleotide polymorphism of Rs3184504 in SH2B3 gene in patients with autoimmune liver disease [J]. Journal of Practical Hepatology, 2024, 27(6): 856-859.
[9]	Gao Yu, Yang Lei, Hu Guangming, et al. Serum macrophage migration inhibitory factor and interleukin-21 levels in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(6): 866-869.
[10]	Gao Yi, Shen Xiaoxue, Xia Suqin, et al. Bile acid composition and their impact of response to immunosuppressant or UCDA therapy in patients with autoimmune hepatitis and primary biliary cholangitis [J]. Journal of Practical Hepatology, 2024, 27(5): 709-712.
[11]	Zhu Jiarui, Ge Shaofeng, Ye Guiyun, et al. Implications of peripheral blood NLR and nCD64 index in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2024, 27(5): 717-720.
[12]	Wang Yanyan, Zhou Tongtong, Bian Zhaolian. Clinical feature and biochemical response to immunosuppressive therapy in patients with primary biliary cholangitis and PBC-autoimmune hepatitis overlapping syndrome [J]. Journal of Practical Hepatology, 2024, 27(5): 721-724.
[13]	Ren Yan, Kong Ming, Xu Manman, et al. Predictive performance of transient elastography and other common non-invasive diagnostic models in predicting histological fibrosis staging in patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2024, 27(5): 725-728.
[14]	Xue Lina, Zhu Guobing, Wu Linlin, et al. Virological response to tenofovir alafenamide in patients with low-level viremia chronic hepatitis B after entecavir treatment [J]. Journal of Practical Hepatology, 2024, 27(4): 519-522.
[15]	Ren Hao, Xiong Qingfang. Diagnostic performance of fournoninvasive detection indexes in predicting liver cirrhosis in patients with autoimmune liver diseases [J]. Journal of Practical Hepatology, 2024, 27(4): 535-538.